Staged multi-target therapy for anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report. (PubMed, Respir Med Case Rep) - Oct 21, 2026 - "Initial intravenous methylprednisolone at 80 mg/day produced limited improvement. Early multi-target escalation included divided-dose methylprednisolone, tofacitinib, short-course intravenous immunoglobulin, Pneumocystis jirovecii prophylaxis and an individualized reduced-dose rituximab regimen consisting of 200 mg followed by three weekly 300-mg infusions. Mycophenolate mofetil was briefly withheld during acute escalation and subsequently resumed for maintenance...Because several interventions overlapped and rituximab has a delayed immunological effect, the early response cannot be attributed to rituximab alone. This case illustrates the potential clinical value of staged multi-target treatment adjustment and infection-risk management in severe anti-MDA5-associated rapidly progressive interstitial lung disease."
Journal • Cough • Dermatomyositis • Immunology • Infectious Disease • Interstitial Lung Disease • Melanoma • Myositis • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • IFIH1
|
|
Lvdan Zhang; Mengwen Jiao; Qingliang Xue; Shaokang Mo; Wei Chen; Yan Hou; Yongjie Qiao; Youchen Jie
|